Support Cancer Research
I confess, this is pretty cool. How do you raise support for your favorite cause and capitalize on social networking? A good place to start is Social Vibe.
SocialVibe is a social media tool that allows people to utilize their online influence to make a real difference. Members choose a brand to endorse, which earns them opportunities to get brand perks and points within SocialVibe. The points that members earn are then turned into funds for the charitable cause of their choice.
The Leukemia and Lymphoma Society are involved and hope to use Social Vibe to raise $5,000 and it doesn’t cost you a penny. Other charity possibilities are updated daily and include Partnership for a Drug Free America, Do Something, The HollyRod Foundation and World Wildlife Fund among others. For more information: http://www.socialvibe.com
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
